医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Biological Industries Announces Poster Presentation at International Society for Cell Therapy Annual Meeting in Singapore

2016年05月23日 PM09:45
このエントリーをはてなブックマークに追加


 

KIBBUTZ BEIT HAEMEK, Israel & CROMWELL, Conn.

Biological Industries (“BI”; www.bioind.com), a leading developer and manufacturer of cell culture media, molecular biology tools, human cytogenetics media, and custom media manufacturing services, is participating and making a poster presentation at ISCT 2016, the annual meeting of the International Society for Cellular Therapy, 25-28 May, in Singapore.

The poster presentation, “A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources,” will be presented by BI’s R&D Product Manager, Mira Genser-Nir, Ph.D.

Presentation Details

  • Abstract Number: 205
  • Presentation Title: A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources
  • The poster will be available for the duration of the conference

“Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells that can be isolated from various tissues as well as generated in vitro from hESCs and iPS cells,” observed Dr. Genser-Nir. “In order for hMSCs to become the cells of choice for use in regenerative medicine and drug screening, the culture conditions must be improved and differentiation potential is required. We feel that this paper represents a big step toward addressing these issues.”

BI will also have a booth at the conference, #C07-C09.

More information on ISCT 2016 is available at www.isct2016.com.

About Biological Industries

BIOLOGICAL INDUSTRIES (BI) develops, manufactures, and supplies life science products to universities, government research, healthcare institutions, and the biopharmaceutical industry. For over 30 years, BI has been working alongside some of the world’s leading academic researchers and institutes in the development of cell culture media, stem cell reagents, and molecular biology tools. BI also offers custom media development and manufacturing services through its ISO 13485:2003 certified cGMP facilities. BI currently supplies products to researchers and clinicians in over 40 countries with products currently in clinical trials. BI is leveraging their industry-leading experience in cell culture media and pluripotent stem cell technology to help facilitate breakthroughs in stem cell research worldwide. BI is committed to a Culture of Excellence by providing the highest quality reagents and cost-effective, innovative products and services tailored to a customer’s specific needs.

To receive ongoing BI communications, please join our email list or connect with the company on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160523005816/en/

CONTACT

Media:
Gotham
Communications
for Biological Industries
Bill
Douglass
, +1-646-504-0890
bill@gothamcomm.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表